ebola
outbreak
west
africa
expert
panel
establish
instruct
uk
prime
minist
identifi
prioriti
pathogen
outbreak
diseas
potenti
caus
futur
epidem
total
prioriti
pathogen
identifi
led
prioritis
spend
emerg
diseas
vaccin
research
develop
uk
meet
report
summaris
process
use
develop
uk
pathogen
prioriti
list
compar
list
gener
organis
world
health
organis
nation
institut
allergi
infecti
diseas
summaris
clinic
progress
toward
develop
vaccin
prioriti
diseas
clear
technic
progress
toward
develop
vaccin
howev
avail
vaccin
depend
sustain
fund
clinic
trial
prepar
clinic
accept
manufactur
materi
interepidem
period
reemerg
zika
viru
sinc
ebola
outbreak
west
africa
highlight
risk
epidem
infecti
diseas
still
pose
outbreak
stimul
reexamin
prioriti
research
develop
vaccin
diseas
nation
intern
level
uk
vaccin
research
develop
network
ukvn
set
instruct
british
prime
minist
expert
work
group
conven
map
prioriti
pathogen
capabl
caus
futur
epidem
subsequ
meet
group
occur
progress
revis
prioriti
pathogen
consid
report
summaris
find
meet
review
intern
emerg
diseas
vaccin
research
develop
landscap
ebola
outbreak
mark
paradigm
shift
attitud
govern
intern
organis
high
impact
epidem
infecti
diseas
prior
diseas
epidem
dealt
larg
reactiv
basi
coordin
develop
diseas
control
strategi
vaccin
antivir
drug
occur
respons
larg
scale
outbreak
although
good
academ
research
trend
emerg
basic
biolog
outbreak
diseas
often
avail
almost
invari
stall
level
demonstr
immunogen
effect
small
scale
trial
anim
model
ebola
viru
outbreak
follow
pattern
intensif
research
effort
follow
major
outbreak
previous
seen
diseas
sar
mer
coronavirus
exampl
search
ncbi
pubm
ebola
vaccin
reveal
origin
scientif
report
exclud
review
articl
year
period
compar
report
year
period
juli
howev
hope
coordin
clinic
research
epidem
diseas
follow
outbreak
critic
technolog
transfer
pilot
method
suitabl
larg
scale
vaccin
manufactur
larg
outbreak
pathogen
aris
although
remain
question
regard
long
term
sustain
commerci
vaccin
emerg
potenti
emerg
epidem
diseas
factor
previous
limit
vaccin
develop
beyond
small
laboratori
scale
address
possibl
conduct
phase
iiiii
clinic
trial
outbreak
least
part
ring
vaccin
strategi
demonstr
highlight
prototyp
vaccin
trial
need
better
integr
emerg
respons
protocol
outbreak
caveat
trial
need
care
manag
commun
affect
must
activ
engag
prevent
misunderstand
research
also
perform
research
outbreak
present
extra
challeng
compar
similar
research
conduct
endem
diseas
partnership
research
local
health
author
need
quickli
effect
establish
local
regulatori
ethic
approv
must
grant
vaccin
trial
ideal
local
physician
recruit
deliv
vaccin
monitor
patient
sometim
factor
addit
complic
lack
local
infrastructur
power
water
internet
access
hamper
storag
administr
larg
batch
vaccin
fundament
problem
fund
trial
vaccin
emerg
epidem
diseas
outbreak
potenti
vaccin
commerci
attract
prior
outbreak
interepidem
period
given
cost
extend
timefram
develop
licens
manufactur
new
vaccin
understand
commerci
prioriti
lie
endem
diseas
wealthi
countri
predict
market
vaccin
everi
year
emerg
outbreak
diseas
sporad
definit
although
outbreak
larg
long
period
outbreak
therefor
guarante
market
vaccin
product
context
willing
govern
intergovernment
organis
support
commerci
scale
vaccin
develop
invest
establish
bank
experiment
vaccin
key
prepared
futur
outbreak
import
intern
commun
develop
strateg
approach
avoid
duplic
ensur
gap
cover
obvious
unit
state
govern
agenc
uniqu
addit
object
address
vaccin
bioterror
agent
overal
coalit
epidem
prepared
innov
cepi
good
posit
promot
cooper
approach
emerg
diseas
vaccin
develop
publicli
fund
initi
limit
resourc
demand
priorit
pathogen
target
vaccin
develop
case
ukvn
priorit
base
expert
review
avail
inform
diseas
repres
known
potenti
threat
epidem
diseas
cross
referenc
state
vaccin
avail
diseas
specif
criteria
inclus
list
includ
case
fatal
rate
cfr
disabl
burden
diseas
regular
outbreak
evid
geograph
spread
zoonot
impact
eas
transmiss
anim
host
human
diseas
zoonot
potenti
humantohuman
transmiss
avail
diagnost
platform
exist
invest
develop
stage
current
vaccin
final
whether
evid
infectiondiseas
could
treat
effect
anoth
intervent
review
panel
includ
individu
expertis
epidemiolog
vaccin
develop
well
infecti
diseas
expert
human
anim
health
repres
major
uk
fund
bodi
mrc
bbsrc
wellcom
trust
depart
health
social
care
panel
specif
focuss
diseas
potenti
caus
high
impact
epidem
human
anim
diseas
includ
consider
substanti
zoonot
potenti
exampl
rift
valley
fever
influenza
viru
exclud
ground
remain
separ
fund
rout
develop
vaccin
emerg
pandem
influenza
subtyp
long
list
epidem
diseas
suitabl
vaccin
avail
devis
subsequ
reduc
list
prioriti
pathogen
scientif
expert
panel
vote
system
fig
base
late
stage
commerci
vaccin
develop
dengu
viru
vaccin
research
subsequ
deprioritis
total
million
us
million
ukvn
alloc
spent
fund
specif
project
address
initi
prioriti
list
origin
list
review
two
year
identifi
gap
revis
necessari
addit
ukvn
organis
around
world
undertaken
similar
outbreak
pathogen
prioritis
process
gener
list
prioriti
pathogen
group
review
criteria
assess
prioritis
use
base
criteria
human
transmiss
medic
countermeasur
sever
case
fatal
rate
humananim
interfac
public
health
context
affect
area
potenti
societ
impact
evolutionari
potenti
blueprint
basi
select
prioriti
diseas
vaccin
develop
numer
fund
agenc
includ
cepi
us
nation
institut
allergi
infecti
diseas
niaid
also
prioritis
pathogen
base
transmiss
mortal
requir
public
health
prepared
although
specif
take
account
avail
vaccin
niaid
prioriti
list
includ
mani
pathogen
outbreak
type
diseas
might
expect
given
similar
focu
organis
promot
human
health
consider
overlap
list
fig
bunyavirus
rift
valley
fever
crimean
congo
haemorrhag
fever
filovirus
ebola
marburg
paramyxoviru
nipah
arenaviru
lassa
fever
coronaviru
middl
east
respiratori
syndrom
appear
prioriti
list
also
includ
hendra
sever
acut
respiratori
syndrom
coronaviru
ukvn
includ
chikungunya
q
fever
niaid
includ
smallpox
anthrax
botul
new
world
arenavirus
lujo
junin
machupo
guanarito
chapar
virus
prioriti
list
hantaviru
plagu
share
niaid
ukvn
list
emerg
yet
unknown
diseas
diseas
x
specif
account
blueprint
cepi
ukvn
list
differ
reflect
differ
prioriti
organis
compil
list
uncertain
natur
prioritis
diseas
current
intermitt
problem
differ
part
world
often
differ
list
result
small
variat
perceiv
risk
diseas
member
review
panel
part
consequ
fact
surveil
data
mani
outbreak
diseas
limit
import
driver
contribut
outbreak
poorli
characteris
exampl
ukvn
prioritis
hantaviru
plagu
chikungunya
q
fever
long
list
hendra
sar
ukvn
long
list
final
list
futur
prioritis
exercis
would
facilit
better
surveil
inform
prioriti
diseas
would
includ
serosurveil
data
risk
popul
identifi
assess
whether
chang
immun
popul
level
link
risk
outbreak
sinc
onset
west
african
ebola
viru
outbreak
notabl
progress
toward
control
diseas
prioriti
list
particularli
ebola
viru
approv
vaccin
ebola
viru
arguabl
lack
effect
vaccin
use
emerg
situat
one
factor
contribut
size
durat
outbreak
effect
vaccin
produc
test
outbreak
may
prove
import
futur
control
avail
late
make
signific
impact
diseas
control
notabl
democrat
republ
congo
repeat
ebola
viru
outbreak
sinc
outbreak
vaccin
avail
vaccin
test
west
africa
outbreak
djera
case
death
outbreak
neighbour
bikoro
iboko
wangata
ntondo
june
case
death
confirm
ebola
case
date
peopl
countri
vaccin
rvsvzebov
vaccin
use
ring
vaccin
strategi
addit
current
current
outbreak
east
drc
peopl
vaccin
alway
particularli
challeng
assess
impact
vaccin
diseas
outbreak
situat
particular
quantifi
case
occur
due
vaccin
rather
number
observ
case
unlik
endem
diseas
baselin
diseas
incid
emerg
epidem
diseas
natur
rel
unpredict
number
case
occur
without
intervent
ring
vaccin
trial
guinea
case
ebola
occur
vaccin
delay
contrast
case
day
vaccin
individu
vaccin
provis
immedi
thu
provid
evid
vaccin
may
save
live
addit
rvsvzebov
vaccin
sever
promis
ebov
vaccin
undergon
clinic
preclin
develop
sinc
tabl
pathogen
ukvn
prioriti
list
progress
toward
clinic
develop
vaccin
mix
licens
tetraval
dengu
vaccin
manufactur
sanofi
pasteur
recombin
viru
base
yellow
fever
attenu
vaccin
backbon
due
concern
antibodi
depend
enhanc
diseas
vaccin
recommend
particular
age
group
endem
area
prescreen
antibodi
respons
indic
prior
dengu
exposur
second
attenu
tetraval
dengu
vaccin
develop
takeda
shown
promis
result
phase
clinic
trial
two
licens
inactiv
hantaviru
vaccin
avail
south
korea
hantavax
china
hfr
vaccin
vaccin
avail
elsewher
inactiv
plagu
vaccin
manufactur
sinc
howev
current
vaccin
type
market
term
new
vaccin
plagu
two
candid
reach
phase
clinic
trial
tabl
subunit
vaccin
base
recombin
v
plagu
antigen
phase
trial
also
complet
vaccin
chikungunya
rift
valley
fever
viru
although
chikungunya
vaccin
like
reach
market
faster
sinc
develop
driven
commerci
organis
rvfv
vaccin
test
us
armi
therefor
may
immedi
avail
gener
popul
interest
note
new
rvfv
vaccin
develop
anim
vaccin
date
trial
vaccin
human
vaccin
pathogen
ukvn
list
less
well
develop
immunogen
zikv
sar
cchf
reach
phase
clinic
trial
case
zikv
also
good
chanc
taken
forward
advanc
clinic
test
encourag
preclin
vaccin
data
exist
cchfv
bulgarian
ministri
health
produc
vaccin
base
inactiv
cchfv
reliabl
human
efficaci
data
exist
recent
turkish
formalin
inactiv
vaccin
report
test
clinic
human
tabl
q
fever
vaccin
avail
australia
manufactur
seqiru
report
effect
howev
vaccin
current
licens
countri
lassa
nipah
vaccin
use
human
progress
beyond
preclin
test
howev
cepi
recent
fund
five
larg
vaccin
programm
lassa
like
lead
earli
clinic
trial
one
key
observ
emerg
consider
exist
new
vaccin
differ
countri
licenc
process
level
prior
efficaci
data
requir
substanti
affect
time
new
vaccin
take
reach
market
term
vaccin
technolog
rang
differ
approach
proven
effect
inactiv
viru
vaccin
shown
effect
rang
prioriti
pathogen
arguabl
lowest
level
technolog
develop
requir
drawback
safeti
issu
relat
grow
prepar
hundr
litr
highli
pathogen
viru
potenti
incomplet
inactiv
requir
multipl
dose
vaccin
achiev
immun
protect
recombin
viru
vaccin
genom
one
viru
modifi
express
antigen
anoth
pathogen
also
success
vsv
mva
human
chimp
adenovirus
measl
effect
deliveri
foreign
antigen
stimul
strong
immun
respons
use
measl
vector
vaccin
addit
advantag
may
provid
addit
protect
endem
human
diseas
measl
subunit
vlp
vaccin
plagu
chikungunya
also
test
clinic
trial
also
evid
nucleic
acid
dna
mrna
base
vaccin
immunogen
human
diseas
although
tabl
vaccin
report
test
clinic
ukvn
prioriti
diseas
peer
review
result
avail
refer
includ
otherwis
clinicaltrialsgov
identifi
list
rv
recombin
viru
vaccin
iv
inactiv
viru
vaccin
ib
inactiv
bacteri
vaccin
vlp
viru
like
particl
vaccin
sub
subunit
vaccin
n
nanoparticl
igg
therapeut
antibodi
dna
dna
vaccin
vsv
vesicular
stomat
viru
replic
defect
human
adenoviru
type
strictli
vaccin
develop
therapeut
antibodi
use
post
exposur
outbreak
develop
mer
coronaviru
may
particularli
use
outbreak
type
diseas
provid
effect
field
signific
challeng
remain
control
epidem
diseas
despit
clearli
defin
prioriti
term
pathogen
select
particular
earli
identif
reaction
outbreak
critic
need
provid
sustain
invest
surveil
diseas
outbreak
map
predict
outbreak
risk
may
help
guid
resourc
alloc
respect
infrastructur
develop
surveil
need
surveil
complic
requir
monitor
diseas
x
previous
unknown
pathogen
major
impact
health
outbreak
recent
advanc
sequenc
technolog
led
identif
mani
previous
unknown
virus
like
increas
even
effort
sequenc
dna
rna
eukaryot
includ
wildlif
new
virus
pose
threat
human
health
identifi
time
manner
one
major
challeng
modern
surveil
underlin
import
intern
collabor
includ
low
incomeendem
diseas
countri
anoth
challeng
implement
nagoya
protocol
respect
use
sampl
low
middl
incom
countri
previous
countri
could
control
physic
export
sampl
ensur
agreement
sampl
could
use
advent
portabl
sequenc
devic
use
field
gene
synthesi
technolog
possibl
design
produc
new
vaccin
start
sequenc
data
without
physic
transfer
materi
current
rel
diseas
caus
bacteria
appear
prioriti
list
larg
relat
effect
antibiot
treatment
howev
threat
emerg
previous
unknown
diseas
must
balanc
emerg
antimicrobi
resist
known
bacteri
pathogen
technic
challeng
around
unwant
advers
effect
vaccin
associ
dengu
vaccin
develop
vaccin
use
resourc
poor
set
real
like
eventu
overcom
challeng
address
neg
attitud
result
vaccin
hesit
popul
would
benefit
routin
vaccin
outbreak
type
diseas
protect
wider
commun
question
whether
wildlif
popul
vaccin
zoonot
diseas
also
need
address
also
vaccin
livestock
diseas
first
infect
livestock
human
may
highli
effect
way
prevent
new
human
diseas
outbreak
time
cost
requir
achiev
licensur
livestock
vaccin
consider
lower
human
vaccin
vaccin
sheep
cattl
goat
rvfv
pig
nipah
sheep
cchfv
camel
mer
could
prevent
human
infect
last
two
exampl
diseas
caus
signific
econom
loss
vaccin
livestock
would
difficult
introduc
inde
primari
reason
livestock
vaccin
benefit
human
public
health
uptak
farmer
would
low
unless
benefit
commun
clear
commerci
cost
farmer
vaccin
commerci
polit
challeng
associ
epidem
diseas
signific
sinc
outbreak
sporad
invest
tend
wane
outbreak
establish
emerg
diseas
vaccin
research
develop
especi
progress
prototyp
vaccin
proof
clinic
efficaci
includ
fund
preclin
trial
nonhuman
primat
new
cepi
initi
may
overcom
problem
import
momentum
toward
develop
effect
vaccin
maintain
even
absenc
recent
outbreak
second
polit
challeng
highlight
west
africa
recent
outbreak
drc
vital
local
commun
activ
engag
vaccin
test
process
avoid
disinform
furthermor
crucial
local
govern
healthcar
agenc
fulli
integr
diseas
outbreak
respons
sinc
arriv
cepi
provid
strong
financi
support
develop
mer
nipah
lassa
vaccin
toward
phase
studi
donor
commit
us
million
date
cepi
still
lack
financi
forc
wellcom
trust
gate
foundat
cepi
donor
us
govern
civil
militari
programm
largest
sponsor
vaccin
prioriti
list
signific
state
contributor
includ
uk
norway
china
india
emerg
vaccin
player
govern
fund
mechan
transpar
time
corpor
vaccin
fund
remain
import
global
r
spend
estim
us
billion
purchas
power
pariti
basi
commerci
viabl
vaccin
alreadi
discuss
particular
issu
vaccin
epidem
diseas
vaccin
develop
lab
bench
registr
cost
us
billion
largescal
manufactur
plant
cost
anoth
us
billion
without
guarante
sale
incent
compani
invest
vaccin
develop
case
biosecur
vaccin
anthrax
smallpox
us
govern
fund
manufactur
purchas
vaccin
stockpil
question
whether
intern
public
sector
guarante
purchas
manufactur
prioriti
list
vaccin
use
platform
technolog
develop
commerci
emerg
pathogen
vaccin
would
obviat
need
build
separ
largescal
manufactur
plant
order
produc
stockpil
emerg
pathogen
vaccin
note
growth
indian
vaccin
manufactur
make
dose
year
top
four
vaccin
manufactur
back
suppli
indian
public
sector
market
grow
sale
intern
public
sector
exampl
unicef
although
futur
outbreak
may
result
yet
unknown
poorli
understood
pathogen
excus
govern
prepar
known
threat
diseas
x
repres
hardest
scenario
prepar
howev
previou
emerg
diseas
outbreak
associ
pathogen
alreadi
describ
pathogen
close
relat
explor
platform
vaccin
technolog
known
prioriti
pathogen
logic
progress
vaccin
develop
known
threat
fieldreadi
state
may
also
provid
springboard
develop
vaccin
new
relat
diseas
clearli
time
taken
develop
even
modifi
vaccin
requir
epidemiolog
approach
use
primari
focu
diseas
control
howev
vital
approach
integr
test
new
vaccin
end
imper
undertak
phase
ii
safeti
immunogen
studi
produc
vaccin
stockpil
interepidem
period
vaccin
avail
rapid
deploy
compliment
establish
outbreak
control
effort
permit
collect
valuabl
clinic
efficaci
data
